FibroGenesis is a regenerative medicine company based in Houston, TX, dedicated to developing innovative treatments for chronic diseases using fibroblasts, a type of cell found in the human body that has shown superior regenerative and anti-inflammatory properties compared to stem cells. With a focus on diseases such as cancer, diabetes, multiple sclerosis, Parkinson's, and colitis, FibroGenesis aims to revolutionize modern medicine by harnessing the potential of fibroblasts as a promising allogenic cell therapy.
With an impressive portfolio of 260 U.S. and international patents, FibroGenesis is at the forefront of medical advancements in cell therapy, targeting various clinical pathways including disc degeneration, chronic traumatic encephalopathy, liver failure, and heart failure. The company's groundbreaking research has garnered attention, with recent achievements including inducing cancer regression using fibroblasts and breakthroughs in preventing COVID-19 blood clotting and lung scarring. FibroGenesis represents a new era in regenerative medicine, offering hope for the cure of chronic diseases through the power of fibroblasts.
Generated from the website